75
Participants
Start Date
April 30, 2005
Primary Completion Date
October 31, 2006
Study Completion Date
November 30, 2006
SB497115
Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
Placebo
Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
GSK Investigational Site, New York
GSK Investigational Site, Marseille
GSK Investigational Site, Berlin
GSK Investigational Site, Hamburg
GSK Investigational Site, Fairfax
GSK Investigational Site, Richmond
GSK Investigational Site, Durham
GSK Investigational Site, Hanover
GSK Investigational Site, Pessac
GSK Investigational Site, Detroit
GSK Investigational Site, Vandœuvre-lès-Nancy
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Clermont Ferrand Cédex 1
GSK Investigational Site, St Louis
GSK Investigational Site, Homburg
GSK Investigational Site, Heidelberg
GSK Investigational Site, Lyon
GSK Investigational Site, Lyon
GSK Investigational Site, Paris
GSK Investigational Site, San Antonio
GSK Investigational Site, Denver
GSK Investigational Site, Clichy
GSK Investigational Site, Boston
GSK Investigational Site, Nice
GSK Investigational Site, San Juan
GSK Investigational Site, Bristol
GSK Investigational Site, Glasgow
GSK Investigational Site, Nottingham
GSK Investigational Site, London
GSK Investigational Site, London
Lead Sponsor
GlaxoSmithKline
INDUSTRY